Roche dumps 4 eye, CNS and cancer drugs in Q4 clear-out

Roche logo

Swiss major Roche announced its financials today, and buried within its pipeline updates the company announced it was dumping a host of early- and late-stage candidates.

In phase 3 it has removed lampalizumab (RG7417), which last fall flopped two tests: Chroma and Spectri, which were assessing the drug in geographic atrophy (GA) due to age-related macular degeneration (AMD), and secondary to AMD.

Jefferies had tipped this drug to top out at $2 billion a year, but it has now been relegated to the Roche dustbin.

Featured Webinar

From Concept to Market: Overcoming the Challenges of Manufacturing and Clinical Trials

In this webinar we will reveal the inner workings of the manufacturing and pharmacy department of a CRO/CDMO, so you understand the different regulatory and operational considerations faced by a clinical research pharmacy.

Learn how CRO/CDMOs successfully address operational and regulatory challenges for pharmaceutical and biotechnology clients; and how this can make the difference between study success or failure.

RELATED: Phase 3 fail puts Roche blockbuster-to-be on the critical list

Further back in phase 1 it’s also canning work on two cancer drugs: RG7986, an antibody drug conjugate for refractory B-cell non-Hodgkin’s lymphoma, and RG6047, which was being tested in metastatic estrogen receptor-positive, HER2-negative breast cancer.

The B-cell med had in fact been developed via Seattle Genetics' ADC tech. RG7604, meanwhile, is a small molecule PI3 kinase inhibitor.

And finally, it’s also curtains for RG7203, a small molecule inhibitor of phosphodiesterase 10A (PDE10A) for the treatment of schizophrenia.

RELATED: Roche dumps lead asset from its $725M Seragon buy


Suggested Articles

Xevinapant in combination with standard cisplatin-based chemoradiation therapy (CRT) reduces the risk of death in high-risk patients with locally adva

The agency also gave the company’s diagnostic, run on the high-throughput Panther Fusion laboratory platform, a green light for pooled testing.

Smith & Nephew has signed up to acquire Integra LifeSciences’ orthopedics business focused on the growing upper and lower extremity markets.